jimmy Turano

FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM

Good report Mike as usal. I would like to know Mike,if you, or Adam Feuerstein, or Shulman, or any other Biotech/Pharma writer, would finally
give a proper prospective to invesotrs on 'MRNA'.
There are so many other companies that you report on, Adam reports on, and even Shulman reports on, that warrant a serious look at potentially investing in them. Month after Month
you actually come up with key companies, and reasons why investors should take a second look at these very special companies.. And each of them vary in stock price from low to medium prices. But when investors become obsessed with a stock soley because of potential and because of a cheap price, they possibly are tying their money up in the wrong company and for great lengths of time. By doing so, there is no guarantee of success, and long term the risk factor may deminish more than half their investment overall.
CAN YOU OR SOMEONE WITH YOUR BACKGROUND AND KNOWLEDGE, EMBELLISH YOUR PERSPECTIVE ON
MDRNA INC(MRNA) TO MAKE INVESTORS AWARE OF THE REAL DANGERS AFFILIATED WITH INVESTING WITH 'MRNA' AT THIS CURRENT TIME.
It would be a great public service to all
THANK YOU